Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis

• Published in: PloS one Vol. 12; no. 6; p. e0178699
• Main Authors: Bolignano, Davide, Cernaro, Valeria, Gembillo, Guido, Baggetta, Rossella, Buemi, Michele, D’Arrigo, Graziella
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.06.2017; Public Library of Science (PLoS)
• Subjects: Adults; Antioxidants; Antioxidants (Nutrients); Antioxidants - administration & dosage; Antioxidants - adverse effects; Ascorbic acid; Biology and Life Sciences; Chronic kidney failure; Clinical trials; Creatinine; Criteria; Damage; Design analysis; Design engineering; Development and progression; Diabetes; Diabetes mellitus; Diabetic Nephropathies - pathology; Dietary Supplements; Disease Progression; Dosage and administration; End-stage renal disease; Health aspects; Heterogeneity; Humans; Internet; Intervention; Kidney diseases; Kidney transplantation; Kidneys; Language; Medicine and Health Sciences; Meta-analysis; Methionine; Nephrology; Oxidative stress; Patients; Peritoneal dialysis; Physical sciences; Physiology; Proteinuria; Renal function; Retarding; Searching; Selenium; Studies; Supplements; Therapy; Tocopherol; Ubiquinone; Vitamin A; Vitamin C; Vitamin E; Zinc; United Arab Emirates
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0178699

Oxidative stress is a key player in the genesis and worsening of diabetic kidney disease (DKD). We aimed at collecting all available information on possible benefits of chronic antioxidant supplementations on DKD progression. Systematic review and meta-analysis. Adults with DKD (either secondary to type 1 or 2 diabetes mellitus). Cochrane CENTRAL, Ovid-MEDLINE and PubMed were searched for randomized controlled trials (RCTs) or quasi-RCTs without language or follow-up restriction. Any antioxidant supplementation (including but not limited to vitamin A, vitamin C, vitamin E, selenium, zinc, methionine or ubiquinone) alone or in combination. Primary outcome was progression to end-stage kidney disease (ESKD). Secondary outcomes were change in albuminuria, proteinuria, serum creatinine and renal function. From 13519 potentially relevant citations retrieved, 15 articles referring to 14 full studies (4345 participants) met the inclusion criteria. Antioxidant treatment significantly decreased albuminuria as compared to control (8 studies, 327 participants; SMD: -0.47; 95% CI -0.78, -0.16) but had apparently no tangible effects on renal function (GFR) (3 studies, 85 participants; MD -0.12 ml/min/1.73m2; 95% CI -0.06, 0.01). Evidence of benefits on the other outcomes of interest was inconclusive or lacking. Small sample size and limited number of studies. Scarce information available on hard endpoints (ESKD). High heterogeneity among studies with respect to DKD severity, type and duration of antioxidant therapy. In DKD patients, antioxidants may improve early renal damage. Future studies targeting hard endpoints and with longer follow-up and larger sample size are needed to confirm the usefulness of these agents for retarding DKD progression.